Haemonetics Corporation (HAE) — Analysis Summary
Haemonetics Corporation (HAE) has a market cap of $5.55B with year-over-year revenue growth of -2.0%. Net margin stands at 7.3%. The stock trades at a P/E ratio of 57.7.
Key Takeaways
- Revenue changed -2.0% year-over-year
- Net margin of 7.3%
- P/E ratio of 57.7
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, HAE posted revenue growth of -2.0% and trades at a P/E of 57.7.
Haemonetics Corporation (HAE)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsWatch List
Some caution signals are active and should be weighed alongside the valuation work.
Debt/EBITDA at 4.3x — elevated leverage
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The Plasma segment includes end-to-end collection technologies, automated plasmapheresis systems (such as the NexSys PCS device), and donor management software designed for commercial plasma collectors. Hospital segment includes Blood Management Technologies (hemostasis analyzers, cell salvage systems) and Interventional Technologies. And the Blood Center provides solutions and devices enabling blood centers to harvest essential components like platelets and red blood cells.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
3,009
Headquarters
BOSTON, MA
Exchange
XNYS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.